Official notice: 177 drugs have been discontinued

on the evening ofNovember 16th, Gansu Provincial Public Resources Trading Bureau issued a notice on matters related to the cancellation of the winning bid registration network for applications for withdrawal of waste drugs (36th batch), 215 drugs from81 enterprises recently submitted applications for withdrawal due to production line modification, rising costs, shortage of raw materials, discontinuation, etc., which could not guarantee the normal supply of medical institutions in Gansu Province. Of these, 177 were discontinued due to discontinuation, according to Cypress Blue.According to Cypress Blue Combs, the drugs that applied for removal were amoxicillin dry suspension, azithromycin particles, hydrochloric acid Azasjung injections, Anlu painkillers, aminophen pseudo-methamine tablets, injections of liver cell growth hormone Dansan injection, dositamine injection, cold clear capsule, hydrochloric acid renitin tablets, Malay acid chlorobenamide tablets, chloretamine tablets, saldamine alcohol aerosols, injection of thymus pentapeptide and so on.According to the notice, this batch has 9 exclusive varieties (10 product regulations) to apply for removal, such as:Chengdu Dikang Pharmaceutical Co., Ltd. Bao Coughing particles, Shenyang Shuangding Pharmaceutical Co., Ltd.'s nasal drip nasal agent, Zhejiang Zhenyuan Pharmaceutical Co., Ltd.'s pounce pseudo-hemp tablets, Ha Pharmaceutical Group World Pharmaceutical Factory's crown heart Tai Maru, Xinhe Aid Pharmaceutical Co., Ltd.'s cat claw grass capsules, Xi'an Bikang Pharmaceutical Group Co., Ltd.'s flat collapse, Inner Mongolia Huifeng Pharmaceutical Co., Ltd.'s children's double solution diarrhea particles, Guizhou Taihe Pharmaceutical Co., Ltd.'s lipid flat capsules, Tianda Pharmaceuticals (Zhuhai) Co., Ltd.'s lipids (8g x 6, 8g x 10).It is not difficult to see that the exclusive varieties of applications for abolition are mainly Chinese medicine. In addition, the application for the removal of 28 varieties of 30 product regulations in Gansu Province, the exclusive winning list of drugs, as well as 175 other scrap drugs.

other dosage forms, specifications to replace the supplyIn view of the above-mentioned drugs, Gansu Provincial Public Resources Trading Bureau in the notice, the exclusive or exclusive winning drugs, medical institutions may choose the same function of the main treatment of alternative drugs procurement;The notice pointed out that from November 20, 2020, the suspension of the suspension of the withdrawal of drugs in the winning bid hanging network qualification, and in accordance with the relevant provisions of the Gansu Province Drug Centralized Procurement Integrity Management Measures to give enterprises the corresponding level of integrity assessment - of which the new sunshine hanging network drugs in 1 year to remove the waste, 1 bad record of a drug, hanging the net 1 to 2 years to apply for removal, according to the batch integrity assessment;And for reasons such as force majeed force, the Drug Administration revokes the approval number, the enterprise shuts down and transfers and other reasons to apply for removal, in principle, can be exempted from processing. However, if the enterprise provides false suspension, withdrawal of the declaration information to avoid the integrity assessment, once verified, from the re-addition processing.For the same variety, different specifications and dosage forms related to the problem, Liaoxi Pharmaceutical Chain Co. , Ltd. practicing pharmacist Li Sibo from a professional point of view to Saibai Blue analysis pointed out that the same drug has different specifications, such as tablets have 10 mg, 20 mg, that is, each dose of the drug is different. Such as anti-blood pressure medicine, individuals can according to their own circumstances, under the guidance of a doctor to choose the appropriate specifications. Different specifications for patients, the choice is greater, easy to take.Specifically, enterprises to develop different dosage forms and specifications of drugs, for patients to take a good dose to master, according to their own condition, take the appropriate dose, of course, must be under the guidance of a doctor; The greatest efficacy; for customers, not to open tablets to take, because some drug tablets can not be opened, such as slow release tablets, controlled release tablets, etc. ; It is more convenient and beneficial for drugs to go to market.As for the different dosage forms of drugs, customers can choose the appropriate dosage form, more convenient to use, such as children can choose oral liquid, oral dosage form is safer, convenient, injections are quick.

drug withdrawal network, the results of the enterprise trade-offOn the issue of a large number of drug discontinuation and withdrawal of the network, a domestic pharmaceutical company executive said to SaibaiLan, before the enterprise in order to bid too low, with the rising costs, the winning bid price is too low, the enterprise naturally can not do.   Some industry analysis of Cypress Blue pointed out that behind the withdrawal of enterprises is actually a trade-off between revenue and cost.   Any pharmaceutical company, even those that produce exclusive varieties, needs to face the trade-off between output and income, and of course pharmaceutical companies at different stages of development have different demands on output and income - some pharmaceutical companies have turned to innovative drugs because of the multiple pressures faced by generic drugs at the policy level, no longer operating at the micro-profit level, and some pharmaceutical companies believe that as long as a variety does not lose money, it can be done, mainly as a supplement to the product line, while developing other market volumes, still rising varieties.   China Merchants Bank Research Institute in an industry research depth report pointed out that, with the medical insurance collection, 4 plus 7 with volume procurement, generic drug consistency evaluation and a series of regulations, low-end generic drug prices fell sharply, market concentration gradually increased, forcing enterprises to abandon the traditional low-end imitation route, on the road of high-end generic drugs, innovative drug research and development.   Anti-tumor drugs accounted for more than half of all clinical applications for new NMPA drugs in 2019, and data show that the circuit has become the most valued and competitive track in innovative drug development.

drug removal from the network, more and more common   According to combing, the general reason for pharmaceutical companies to apply for product removal is the rise of raw materials, production line transformation, drug approval was withdrawn and other reasons.   In addition, there are many provinces in the drug application to cancel the product network qualification, but also require enterprises to submit a unified national non-supply commitment letter, that is, these applications to withdraw the network of drugs, can not be supplied throughout the country.   Drugs because of rising costs, production stoppages and other reasons to apply for the withdrawal of the phenomenon is not uncommon, according to Cypress Blue combing, so far, only pharmaceutical companies actively apply for the withdrawal of drugs on more than 1000, and to base drugs and low-cost drugs, etc.   Heparin sodium injection, hydrochloric acid bubikain injection, double yellowing particles, clearing spirit injection, hydrochloric acid Benapuri tablets, kramycin capsules, compound catoprile tablets, etc. are common de-net varieties.   In addition to enterprises for various reasons to actively apply for the withdrawal of the network, due to the national organization of drug centralized volume procurement was not selected and unwilling to accept price reduction, due to the same varieties of generic drugs over the consistent evaluation of enterprises full of 3, due to the unwillingness to accept the national price linkage, due to the long-term in the recruitment platform has no procurement records and other reasons, the phenomenon of pharmaceutical products withdrawal network can be said to be common.   This phenomenon is likely to continue further with the reform of drug recruitment platforms in the provinces. (
Seber Blue
)